Accessing Medicines in Australia

This page provides general information only about how access to certain medicines is regulated in Australia. It is not medical or legal advice, and it does not facilitate access to any substance. Any decision about a medicine must be made with a registered medical practitioner.

Australia has formal, legally defined pathways through which medicines that are not on the standard register may, in specific circumstances, be accessed. Understanding these pathways helps explain the role of regulators, prescribers and pharmacists, and why the system is deliberately structured around professional oversight rather than direct consumer access. The descriptions below are general summaries; the precise rules are set by the TGA and can change over time.

The Australian Register of Therapeutic Goods (ARTG) is the official register maintained by the TGA. In general, therapeutic goods must be entered on the ARTG before they can be lawfully supplied in Australia.

• Registered (or listed) medicines are on the ARTG and have been through the relevant TGA assessment for their category.
• Unregistered medicines are not on the ARTG. They are not automatically illegal, but they cannot be supplied through normal channels and may only be accessed through specific, regulated pathways.

The existence of these pathways reflects a balance: ensuring oversight and safety while allowing access in defined clinical situations where no suitable registered product is available. The word "unregistered" simply means a product has not gone through the full registration process in Australia; it is a regulatory status, not a verdict on the product itself. A product might be unregistered in Australia for many reasons — for example, because it is newer, because the market here is small, or because its sponsor has not sought registration — none of which is, by itself, a statement about the product's quality. What unregistered status does mean is that the usual route to supply is not available, and that any access must instead go through the controlled pathways described below.

The Special Access Scheme (SAS) is a TGA framework that allows access to unregistered therapeutic goods for individual patients in particular circumstances. It is administered through defined categories:

• Category A — a notification pathway for patients who are seriously ill, with specific eligibility criteria defined by the TGA.
• Category B — an application pathway in which a practitioner applies to the TGA for approval to access an unregistered product for a particular patient.
• Category C — a notification pathway for certain lower-risk products and established uses, as defined by the TGA.

A defining feature of the SAS is that it is centred on the individual patient: it is the treating practitioner who engages with the scheme on behalf of a specific person, having considered that person's situation. The precise rules, eligibility, and obligations for each category are set by the TGA and can change. This page summarises the structure in general terms only; it does not constitute guidance on using any pathway.

The Authorised Prescriber Scheme is a separate pathway under which the TGA may authorise a specific medical practitioner to prescribe a particular unregistered product to a defined class of their patients. Unlike a single-patient SAS application, an authorised prescriber can supply the relevant product to patients in the authorised category without a separate approval each time, within the conditions of their authorisation.

This pathway still operates entirely within professional and regulatory oversight. The authorisation is granted to the practitioner, for a defined scope, and carries reporting and governance obligations, including requirements to report on the patients treated. In other words, it streamlines a defined and approved use; it does not remove the layers of professional responsibility that surround unregistered medicines.

It can seem complicated that Australia maintains both a registration system and a set of separate access pathways. The structure reflects a deliberate trade-off that sits at the heart of medicines regulation everywhere. On one side is the goal of safety: requiring that medicines be assessed for quality, safety and the evidence behind their use before they are widely supplied. On the other is the recognition that, in particular clinical situations, a registered product may not exist or may not suit an individual, and that qualified practitioners need a lawful, controlled way to respond. The access pathways are the mechanism for managing that tension. Crucially, they are not loopholes: each one keeps a registered health professional in the decision-making chain, attaches conditions and reporting obligations, and operates under the authority of the TGA.

Across all of these pathways, registered health professionals are central:

• A registered medical practitioner assesses the individual clinical situation, determines whether an unregistered product may be appropriate, and is responsible for any application or authorisation.
• A pharmacist dispenses the medicine, provides professional guidance on safe use, checks for potential interactions, and forms part of the quality and safety chain.

These professionals carry legal and ethical responsibilities, which is precisely why the pathways are built around them rather than around direct consumer access. Their involvement also means that someone with appropriate training is monitoring how a medicine is used and is available to respond if questions or problems arise.

Importing therapeutic goods into Australia is also regulated. While there are limited personal-importation provisions in defined circumstances, scheduled substances — including prescription-only and controlled substances — are subject to strict controls, and importing them without proper authority can be unlawful. People sometimes underestimate how serious these rules are, and assumptions made from overseas experience do not necessarily apply here.

The single most important principle is this: patients cannot self-prescribe unregistered or scheduled medicines. These pathways are designed to operate through qualified practitioners, not around them. Attempting to obtain such substances outside the regulated system carries legal risks and removes the safety protections the system is built to provide — including assurance of quality, professional assessment of suitability, and ongoing oversight.

This page is general information only and is not medical or legal advice. For any question about access to a medicine, speak with a qualified, registered health practitioner who can consider your individual circumstances.

To draw the threads of this page together:

• The ARTG is the official register of therapeutic goods; in general, products must be on it before they can be supplied normally in Australia.
• "Unregistered" describes a regulatory status, not a judgement on a product, and access to unregistered medicines is possible only through defined pathways.
• The Special Access Scheme generally provides access for individual patients across Categories A, B and C.
• The Authorised Prescriber Scheme authorises a specific practitioner to prescribe a particular unregistered product to a defined class of patients.
• Registered medical practitioners and pharmacists are central to every pathway, carrying legal and ethical responsibilities and providing ongoing oversight.
• Importation of scheduled substances is tightly controlled, and patients cannot self-prescribe.

The thread running through all of this is professional oversight. The system is built so that a qualified practitioner is always involved in deciding whether an unregistered medicine is appropriate, applying for or authorising access, and monitoring its use. It is also worth remembering that the rules summarised here can be updated, and that the details for any particular product or category are determined by the TGA rather than fixed in general descriptions like this one. Understanding the framework can make conversations with your own practitioner clearer, but it is not a substitute for that conversation. As with every page on this site, the information here is general in nature; please seek advice tailored to your circumstances from a qualified, registered health practitioner.